3D biofabrication technology is revolutionising applications across a wide spectrum of industries, including pharmaceuticals, regenerative medicine, drug screening, food and other animal products, cell-based biosensors, and testing of cosmetics and other health care goods. Aleph Objects Inc., manufacturer of LulzBot 3D Printers, announced their collaboration with FluidForm Inc., an innovator in 3D bioprinting.
FluidForm’s FRESH printing technique, developed in Carnegie Mellon University’s Regenerative Biomaterials and Therapeutics Group, enables 3D printing of bioinks and other soft materials. Together, Aleph Objects and FluidForm will combine their expertise to offer new bioprinting solutions, with the initial offering coming soon.
Within the next decade, major pharmaceutical companies will be able to replace some animal testing and non-physiological 2D cell culture systems with clinically-relevant 3D bioprinted human tissues.
3D bioprinting is already being used in labs to create tissue scaffolds and other complex biological structures. ‘We’re still at the very beginning of being able to build real functional tissues with 3D bioprinting,’ said FluidForm CTO Adam Feinberg. ‘Collaborations like the one we are building with LulzBot will help make this a reality faster.’
FluidForm’s novel platform of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D printing enables fabrication of soft, biological scaffolds for applications in tissue engineering and regenerative medicine.
‘Combining proven expertise in professional 3D printers and hardware with 3D biofabrication technology is going to be an absolute game-changer,’ said Aleph Objects CEO and President Grant Flaharty. ‘The market for 3D bioprinters and 3D bioprinted tissues is estimated to grow to R26.4 billion ($1.9 billion) by 2028.’